Revenue and Profit - The company's revenue for Q1 2024 was ¥183,475,935.51, a decrease of 8.63% compared to ¥200,800,387.47 in the same period last year[5] - Net profit attributable to shareholders was ¥8,423,929.99, down 69.56% from ¥27,669,629.76 year-on-year[5] - Total operating revenue for Q1 2024 was CNY 183,475,935.51, a decrease of 8.2% compared to CNY 200,800,387.47 in Q1 2023[19] - Net profit for Q1 2024 was CNY 8,423,929.99, a decline of 69.6% from CNY 27,669,629.76 in Q1 2023[20] - Operating profit decreased significantly to CNY 10,492,562.26, down 69.2% from CNY 34,137,438.81 in the same period last year[20] - Basic earnings per share for Q1 2024 were CNY 0.1220, compared to CNY 0.3945 in Q1 2023[21] Cash Flow - The net cash flow from operating activities increased significantly by 1,099.80%, reaching ¥6,066,863.78 compared to ¥505,655.16 in the previous year[5] - The net cash flow from operating activities for Q1 2024 was 6,066,863.78, a significant increase from 505,655.16 in Q1 2023, reflecting improved operational efficiency[24] - Cash inflow from operating activities totaled CNY 171,252,786.05, an increase from CNY 159,137,413.48 in the previous year[22] - The net cash flow from financing activities was -8,144,375.00, showing a decrease in cash inflow compared to the previous period[24] - The ending balance of cash and cash equivalents decreased to 220,687,086.13 from 363,773,130.46 year-over-year, indicating a cash reduction of approximately 38.9%[24] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,355,537,372.29, reflecting a 1.35% increase from ¥1,337,497,679.93 at the end of the previous year[5] - Total liabilities increased to CNY 275,985,388.92 from CNY 234,311,773.52, indicating a rise in financial obligations[20] - The company’s long-term borrowings reached ¥33,000,000.00, marking a 100% increase due to new bank loans[9] - The company reported a significant increase in contract liabilities from CNY 14,009,811.41 to CNY 21,599,387.56, a rise of approximately 54.4%[16] Investments and Expenses - The company experienced a 136.63% increase in construction in progress, amounting to ¥20,866,684.50, primarily due to the expansion project[9] - Total cash outflow from investing activities was 231,414,389.35, compared to 202,854,882.90 in the previous year, indicating increased investment efforts[24] - Research and development expenses were CNY 1,617,199.72, down from CNY 2,127,675.84 in Q1 2023, indicating a reduction in R&D investment[20] - Sales expenses rose to CNY 60,898,593.76, compared to CNY 59,019,548.45 in the previous year, reflecting increased marketing efforts[20] Shareholder and Equity Structure - The company’s equity structure includes significant holdings by major shareholders, with the largest shareholder holding 28.64%[12] - The company is actively managing its shareholder structure, with several entities involved in financing and equity management[13] - Total equity attributable to shareholders decreased to CNY 1,079,551,983.37 from CNY 1,103,185,906.41, showing a decline in shareholder value[20] Accounting and Reporting - The company did not conduct an audit for the Q1 2024 report, which may affect the perception of financial reliability[26] - The company is implementing new accounting standards starting in 2024, which may impact future financial reporting[25]
恩威医药(301331) - 2024 Q1 - 季度财报